Patents by Inventor Hualiang Jiang

Hualiang Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11464795
    Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 11, 2022
    Assignees: East China University Of Science And Technology, Yunnan University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Honglin Li, Weilie Xiao, Lili Zhu, Lina Quan, Qiao Li, Yanyan Diao, Zhenjiang Zhao, Hualiang Jiang
  • Patent number: 11434226
    Abstract: The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: September 6, 2022
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Jingshan Shen, Yang He, Weiming Chen, Jianfeng Li, Guanghui Tian, Xudong Gong, Zhen Wang, Rongxia Zhang, Yongjian Liu, Hualiang Jiang
  • Patent number: 11427593
    Abstract: The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 30, 2022
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Suzhou Suplead Life Sciences Co., Ltd.
    Inventors: Bing Zhou, Cheng Luo, Zizhou Li, Yaxi Yang, Shijie Chen, Hong Ding, Hualiang Jiang, Gang Qiao, Xinjun Wang, Senhao Xiao
  • Patent number: 11384073
    Abstract: The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 12, 2022
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Jingshan Shen, Yang He, Zhen Wang, Jianfeng Li, Yongjian Liu, Jin Suo, Guanghui Tian, Weiming Chen, Feipu Yang, Yu Wang, Xiangrui Jiang, Rongxia Zhang, Hualiang Jiang
  • Patent number: 11319303
    Abstract: It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: May 3, 2022
    Assignee: WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Cheng Luo, Yuli Xie, Bing Zhou, Zhiyi Yao, Liyan Yue, Wei Wan, Bidong Zhang, Yuanyuan Zhang, Hualiang Jiang, Kaixian Chen
  • Publication number: 20220112177
    Abstract: A ketoamide compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically, the ketoamide compound shown in formula (A), a racemate, an enantiomer, or a diastereoisomer thereof, or any mixture of same, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The ketoamide compound can effectively inhibit coronavirus or Ebola virus, and thereby implement the prevention or treatment of diseases related to coronavirus or diseases related to Ebola virus.
    Type: Application
    Filed: August 9, 2019
    Publication date: April 14, 2022
    Inventors: Hong Liu, Shibo Jiang, Wenhao Dai, Lu Lu, Jingjing Peng, Shuai Xia, Jiang Wang, Jian Li, Hualiang Jiang, Kaixian Chen
  • Publication number: 20220002278
    Abstract: Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.
    Type: Application
    Filed: October 20, 2020
    Publication date: January 6, 2022
    Inventors: Bing Zhou, Cheng Luo, Hualiang Jiang, Yaxi Yang, Lianghe Mei, Wenchao Lu, Senhao Xiao, Shijie Chen, Shili Wan, Gang Qiao, Rukang Zhang
  • Patent number: 11142543
    Abstract: An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: October 12, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Chenggang Huang, Yang Li, Hualiang Jiang, Yang Xie, Fei Guo, Zhixiong Li, Mingcang Chen, Mingyue Zheng, Zhaolin Sun, Yu Gao, Xiaoting Tian, Pei Hu, Bing Zhang
  • Publication number: 20210309648
    Abstract: The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.
    Type: Application
    Filed: December 18, 2020
    Publication date: October 7, 2021
    Inventors: Jingshan Shen, Yang He, Zhen Wang, Jianfeng Li, Yongjian Liu, Jin Suo, Guanghui Tian, Weiming Chen, Feipu Yang, Yu Wang, Xiangrui Jiang, Rongxia Zhang, Hualiang Jiang
  • Publication number: 20210221807
    Abstract: Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.
    Type: Application
    Filed: May 21, 2019
    Publication date: July 22, 2021
    Inventors: Hong LIU, Meiyu GENG, Yu ZHOU, Jian DING, Feifei FANG, Jing AI, Jian LI, Xia PENG, Hualiang JIANG, Yinchun JI, Kaixian CHEN
  • Patent number: 11021457
    Abstract: The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 1, 2021
    Assignee: WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Zhiyi Yao, Cheng Luo, Yuli Xie, Liyan Yue, Wei Wan, Yuanyuan Zhang, Hualiang Jiang, Kaixian Chen
  • Patent number: 11013745
    Abstract: The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: May 25, 2021
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.
    Inventors: Bing Zhou, Cheng Luo, Yaxi Yang, Yuanyuan Zhang, Daohai Du, Hualiang Jiang, Gang Qiao, Xinjun Wang
  • Publication number: 20210101891
    Abstract: Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 8, 2021
    Inventors: Bing Zhou, Cheng Luo, Hualiang Jiang, Yaxi Yang, Lianghe Mei, Wenchao Lu, Senhao Xiao, Shijie Chen, Shili Wan, Gang Qiao, Rukang Zhang
  • Patent number: 10966996
    Abstract: Disclosed is a Glechoma longituba (Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 6, 2021
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, NANJING PAILEXING PHARMACEUTICAL TECHNOLOGY LTD.
    Inventors: Weiliang Zhu, Heyao Wang, Yong Zhang, Peng Sun, Bo Li, Zhijian Xu, Hualiang Jiang, Kaixian Chen
  • Patent number: 10927107
    Abstract: The present invention relates to phenyl [a]indole[2,3-g]quinolizine compounds represented by formula (I), a preparation method therefor, a pharmaceutical composition, and applications thereof. Specific applications are applications in the preparation of drugs for treating diseases related to a proprotein convertase subtilisin Kexin-9 (PCSK9), comprising the applications in the preparation of drugs for treating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver deformation, atherosclerosis, obesity and other metabolic diseases.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 23, 2021
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Yiping Wang, Fei Zhao, Jing Zhao, Jiang Wang, Cong Xi, Chenglin Wu, Hao Shen, Xu Han, Hualiang Jiang, Kaixian Chen
  • Publication number: 20210040066
    Abstract: Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibitory effect on phosphodiesterase (PDE4), and can be used in the prevention, treatment or auxiliary treatment of multiple diseases associated with the activity or expression of phosphodiesterase, especially PDE4-associated immune and inflammatory diseases, such as psoriasis and arthritis.
    Type: Application
    Filed: February 3, 2019
    Publication date: February 11, 2021
    Inventors: Yechun XU, Hong LIU, Wei TANG, Xianglei ZHANG, Zhanni GU, Heng LI, Xu HAN, Fenghua ZHU, Chunlan FENG, Guangyu DONG, Tiantian CHEN, Wuyan CHEN, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20210015824
    Abstract: Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.
    Type: Application
    Filed: March 8, 2019
    Publication date: January 21, 2021
    Inventors: Hong LIU, Jia LI, Jiang WANG, Yi ZANG, Jian LI, Jingya LI, Dandan SUN, Hualiang JIANG, Kaixian CHEN
  • Patent number: 10875883
    Abstract: Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw material, (S)-?3-amino acid is obtained by asymmetric resolution induced by using a nickel chelate, and Maraviroc is synthesized by using (S)-3-amino-3-phenylpropionic acid as a key intermediate with a high yield and the ee value reaching 98.2% or more. The method of the present invention has widely available materials, mild synthetic process conditions, is easy to control, and produces a product of a high optical purity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: December 29, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Jiang Wang, Shengbin Zhou, Panfeng Peng, Yong Nian, Shuni Wang, Shuangjie Shu, Hao Shen, Hualiang Jiang, Kaixian Chen
  • Publication number: 20200385418
    Abstract: An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 10, 2020
    Inventors: Chenggang HUANG, Yang LI, Hualiang JIANG, Yang XIE, Fei GUO, Zhixiong LI, Mingcang CHEN, Mingyue ZHENG, Zhaolin SUN, Yu GAO, Xiaoting TIAN, Pei HU, Bing ZHANG
  • Patent number: 10836743
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 17, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Jia Li, Jiang Wang, Mingbo Su, Shuni Wang, Yubo Zhou, Wei Zhu, Wei Xu, Chunpu Li, Hualiang Jiang, Kaixian Chen